Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267

Journal of Infectious Diseases

Volumn 185, Issue 9, 2002, Pages 1359-1363

  Wohl, David A ^a   Aweeka, Francesca T ^b   Schmitz, John ^a   Pomerantz, Roger ^c   Cherng, Deborah Weng ^e   Spritzler, John ^e   Fox, Lawrence ^f   Simpson, David ^e   Bell, Dawn ^g   Holohan, M K ^g   Thomas, Steven ⁱ   Robinson, Wayne ⁱ   Kaplan, Gilla ^h   Teppler, Hedy ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h ROCKEFELLER UNIVERSITY   (United States)

ⁱ CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELGENE; PLACEBO; THALIDOMIDE;

ADULT; APHTHOUS ULCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WASTING SYNDROME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; THALIDOMIDE;

EID: 0036569235     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340133     Document Type: Article

References (15)

1. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
2. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection
3. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial
4. Thalidomide reverses cachexia in HIV-wasting syndrome
5. Thalidomide in patients with HIV infection, and chronic diarrhea: Double blind placebo controlled clinical trial
6. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis
7. Activity of thalidomide in AIDS-related Kaposi's sarcoma
8. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus
9. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
10. Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects
11. Effects of oral thalidomide on rat liver and skin microsomal P450 isoenzyme activities and on urinary porphyrin excretion: Interaction with oral hexachlorobenzene
12. Determination of thalidomide in plasma and blood by HPLC, avoiding hydrolytic degradation
13. A single dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans
14. Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated with oral aphthous ulcers: AIDS Clinical Trials Group 251
15. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone